Literature DB >> 3921948

Confusion and paranoia associated with oral tocainide.

C W Clarke, E O el-Mahdi.   

Abstract

Two middle aged female patients developed hallucinations and severe confusion with paranoid features during oral tocainide administration at recommended dosage levels. Both patients had evidence of impaired renal function. Symptoms were provoked on re-challenge in the first patient. In the second patient the tocainide blood level was higher than the recommended therapeutic range. Both patients reverted to their normal mental state on withdrawal of the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921948      PMCID: PMC2418129          DOI: 10.1136/pgmj.61.711.79

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias.

Authors:  W Ryan; R Engler; M LeWinter; J S Karliner
Journal:  Am J Cardiol       Date:  1979-02       Impact factor: 2.778

2.  Severe paranoia with concomitant tocainide and propranolol therapy.

Authors:  M Rubino; E Jackson
Journal:  Clin Pharm       Date:  1982 Mar-Apr

3.  Safety evaluation of tocainide in the American Emergency Use Program.

Authors:  H R Horn; Z Hadidian; J L Johnson; H G Vassallo; J H Williams; M D Young
Journal:  Am Heart J       Date:  1980-12       Impact factor: 4.749

4.  Tocainide for refractory ventricular arrhythmias of myocardial infarction.

Authors:  C I Haffajee; J S Alpert; J E Dalen
Journal:  Am Heart J       Date:  1980-12       Impact factor: 4.749

  4 in total
  3 in total

Review 1.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 2.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

3.  Tocainide and myotonic dystrophy.

Authors:  R Harries-Jones
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.